- Home
- MNOV vs HLVX Comparison
MNOV vs HLVX Comparison
Compare MNOV & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- HLVX
- Stock Information
- Founded
- MNOV 2000
- HLVX 2020
- Country
- MNOV United States
- HLVX United States
- Employees
- MNOV N/A
- HLVX 90
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- MNOV Health Care
- HLVX Health Care
- Exchange
- MNOV Nasdaq
- HLVX Nasdaq
- Market Cap
- MNOV 89.8M
- HLVX 92.9M
- IPO Year
- MNOV 2005
- HLVX 2022
- Fundamental
- Price
- MNOV $1.90
- HLVX $1.88
- Analyst Decision
- MNOV Strong Buy
- HLVX Hold
- Analyst Count
- MNOV 1
- HLVX 5
- Target Price
- MNOV $9.00
- HLVX $2.33
- AVG Volume (30 Days)
- MNOV 21.7K
- HLVX 172.5K
- Earning Date
- MNOV 02-18-2025
- HLVX 03-19-2025
- Dividend Yield
- MNOV N/A
- HLVX N/A
- EPS Growth
- MNOV N/A
- HLVX N/A
- EPS
- MNOV N/A
- HLVX N/A
- Revenue
- MNOV N/A
- HLVX N/A
- Revenue This Year
- MNOV N/A
- HLVX N/A
- Revenue Next Year
- MNOV N/A
- HLVX N/A
- P/E Ratio
- MNOV N/A
- HLVX N/A
- Revenue Growth
- MNOV N/A
- HLVX N/A
- 52 Week Low
- MNOV $1.12
- HLVX $1.55
- 52 Week High
- MNOV $2.55
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- MNOV 45.15
- HLVX 46.23
- Support Level
- MNOV $1.87
- HLVX $1.86
- Resistance Level
- MNOV $2.06
- HLVX $1.97
- Average True Range (ATR)
- MNOV 0.08
- HLVX 0.07
- MACD
- MNOV 0.00
- HLVX -0.00
- Stochastic Oscillator
- MNOV 47.48
- HLVX 34.09
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.